CytoSPAR, Inc.

PLANO, TX · Founded 2021 · CIK 0001923117 · Medtech · Private

Direct urine sample phenotypic antimicrobial susceptibility testing platform that identifies effective antimicrobial agents in a single shift

cytospar.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.0M
1 Form D · May 2022
53 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,994,998
Form D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1324SYNCRO MEDICAL INNOVATIONS INC—$2.3M
1325APTUS, LLC—$2.1M
1326Nasseo, Inc.—$2.0M
1327CytoSPAR, Inc.—$2.0M
1328Credence MedSystems, Inc.—$44M
1329ZXEREX CORPORATION—$1.4M
1330Vocxi Health, Inc.—$3.1M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Mark AllenDirector
  • William WeismanDirector
  • Russell WilliamsDirector · Executive Officer

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.